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Introduction
Autoinflammatory diseases (AIDs) are characterized by
recurrent episodes of systemic and organ-specific
inflammation. If unrecognized and untreated, they may
cause significant morbidity and mortality.
Our understanding and management of these disor-
ders has improved markedly over the last decade.
Nevertheless, the majority of children with periodic
fevers do not have mutations in known periodic fever
syndrome genes. Even in patients with known muta-
tions, the clinical phenotype may vary greatly, likely as a
result of the environment. Given the rarity of AIDs,
registries of patients with these disorders have been
established in some countries.
The Childhood Arthritis and Rheumatology Research
Alliance (CARRA) Registry is a multicenter, observa-
tional database of North American children with rheu-
matic diseases, including those with AIDs. Patients with
defined rheumatic diseases who are 21 years of age or
younger and are seen at a CARRA site are eligible to
enroll. This study is the first report of patients with
AIDs within this registry.
Objectives
To describe the demographic data of patients with AIDs
in a North American registry of rheumatic disorders.
Methods
We conducted a cross-sectional study of children and
adolescents with AIDs enrolled in the CARRA Registry.
Enrollment in the database began in May 2011 and our
study included data as of March 1, 2013. Inclusion cri-
teria included diagnoses of specific monogenic and poly-
genic AIDs, as well as suspected AIDs with undefined
diagnoses. Baseline data at enrollment is reported and
analyzed.
Results
As of March 1, 2013, 7,931 patients were enrolled in the
CARRA database. Fifty-one (0.64%) were diagnosed with
AIDs, ranging in ages at enrollment from 2.5 to 20.7
years. There were 28 females (54.9%). Thirty-nine
(76.5%) patients were White, 6 (11.8%) were Latino, and
there were 2 (3.9%) patients from each of the following
ethnic groups: American Indian/Alaskan Native, Black/
African American, and Middle Eastern.
Of the 51 patients with AIDs, 20 (39.2%) had CRMO,
7 (13.7%) had PFAPA, 7 (13.7%) had FMF, 4 (7.8%) had
TRAPS, 2 (3.9%) had MWS, and 1 (2%) patient each
had PAPA, SAPHO, and NOMID. One (2%) patient had
both FMF and TRAPS, and 7 (13.7%) patients had unde-
fined AIDs.
Fifteen (29.4%) patients had genetically confirmed dis-
ease. The average length of time between the onset of
symptoms and the evaluation by a rheumatologist was
1.35 years, ranging from 0.06 to 5 years. At enrollment,
41 (80.4%) patients had an ACR global functional status
of Class I.
The age of onset of each disease varied markedly.
NOMID was diagnosed at birth, while SAPHO had the
latest average age of diagnosis at 13. Average CHAQ
scores ranged from 0 in patients with PAPA and FMF/
TRAPS, to 2.38 in the patient with NOMID. Physician
global score also ranged from 0 for patients with FMF,
PAPA, and FMF/TRAPS, to 8 for the patient with
NOMID.
Conclusion
This study is the first to examine patients with AIDs in
a North American, multiethnic registry. Continued
observation of these patients and enrollment of new
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patients should provide meaningful data on these rare
diseases in order to facilitate diagnosis, optimize treat-
ment, and improve prognosis. We hope that this effort
will encourage further international collaboration to cre-
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